DiaMonTech AG

  • WKN: A255G4
  • ISIN: DE000A255G44
  • Land: Deutschland

Nachricht vom 22.08.2019 | 10:17

DiaMonTech's first product 'DMT Base' receives CE-certification for non-invasive blood glucose monitoring with laser-based technology


DGAP-Media / 22.08.2019 / 10:17

DiaMonTech's first product "DMT Base" receives CE-certification for non-invasive blood glucose monitoring with laser-based technology

Berlin, 22 August 2019 - DiaMonTech GmbH, a young medical technology company, has received the CE certification for its first medical product "DMT Base". The device enables non-invasive blood glucose measurement using laser-based technology. The certification confirms that the patented technology meets the high safety and performance standards for medical devices required for market approval. The label is valid for all countries of the European Union.

"The CE label of our non-invasive blood glucose monitoring device is an important milestone for our company. It is backed by more than 20 years of intensive research and development work. Now our goal is to make this technology available to as many diabetes patients and as quickly as possible, thereby making their lives easier," says Thorsten Lubinski, co-founder and CEO of DiaMonTech GmbH.

The "DMT Base" can be used intuitively: the patient places his finger on a sensor field for a few seconds and the blood sugar level is shown on a display. The blood sugar level can thus be measured precisely and painlessly without a drop of blood. The measurement can be carried out as often as desired without consumables (test strips). For the user, the need to prick several times a day is eliminated.

The "DMT Base" is currently optimised for use in professional environments (e.g. diabetes centres). The smaller "DMT Pocket" is currently under development. This device is intended to be about the size of a smartphone and could therefore be a constant companion for diabetes patients.

About DiaMonTech
DiaMonTech GmbH is a medical technology company that specializes in the development, design and marketing of products for medical diagnostics. The patented photothermal diagnostic technology based on infrared lasers enables the precise measurement of relevant blood parameters. The first application is the non-invasive blood glucose measurement, which enables an accurate and fast measurement without pain. The company aims to launch the smartphone-sized "DMT Pocket" at the end of 2020.

More information about DiaMonTech can be found at www.diamontech.de.

Press Contact
Alexander Neblung
Kirchhoff Consult AG
Phone +49 40 60 91 86 70
E-mail diamontech@kirchhoff.de



End of Media Release


Issuer: DiaMonTech GmbH
Key word(s): Research/Technology

22.08.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Interview im Fokus

Mountain Alliance: „Großer Digitalisierungsschub“

Furioses Börsendebüt für den Datenbankspezialisten Exasol. Einer der Profiteure: Die Münchner Beteiligungsgesellschaft Mountain Alliance AG (MA, ISIN DE000A12UK08), die auch nach einem Teilexit noch rund 2% an Exasol hält. Aktuell notiert die MA-Aktie rund 30 % unter dem NAV. Financial.de sprach mit MA-CEO Daniel Wild über die stärksten Digitalisierungstrends, die kritische Größe von 100 Mio. Euro Börsenwert, den neuen Investor und weitere Aktienkäufe.

GBC-Fokusbox

Aves One AG: Kursziel 13,60 €

Die Aves One AG ist auch in der Corona-Krise als Bestandshalter von langlebigen Logistik-Assets mit langfristigen Mietverträgen gut aufgestellt. Das Unternehmen hat als Guidance einen Umsatz und ein EBITDA mindestens auf Vorjahresniveau verkündet. Unseres Erachtens sollte dies auch ohne Zukäufe gut machbar sein, da die im abgelaufenen Geschäftsjahr 2019 erworbenen Assets bereits zu einer höheren Umsatzbasis führen sollten. Auf Basis unseres DCF-Modells haben wir ein Kursziel in Höhe von 13,60 € ermittelt und vergeben ein KAUFEN-Rating.

News im Fokus

Deutsche Lufthansa AG: Einigung über Lufthansa Stabilisierungspaket

30. Mai 2020, 00:04

Aktuelle Research-Studie

2G Energy AG

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Hinzufügen

29. Mai 2020